Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).
Public ClinicalTrials.gov record NCT07832942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
All living things are made of building blocks called cells. Genes are the part of cells that contain the instructions which determine important things about you, like your height or hair color, and affect your health. DNA is the material in the cells that makes up your genes and your particular make-up is call your genotype. Changes or differences in a gene (your genotype) may affect your chances of developing a particular disease, or how a person responds to a particular drug. Your genes are passed down from your parents and then passed on to your children. Different forms of certain genes in your body, for example, the B2AR gene, can increase your blood pressure. The form of the gene that could raise your blood pressure is called the risk allele or risk genotype. Taking too much salt in your food or drink also can increase your blood pressure. In this research study we want to determine if different forms of the B2AR gene and the level of salt intake act together to cause high blood pressure.
Study identification
- NCT ID
- NCT07832942
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- low sodium diet Other
- high sodium diet Other
- renal plasma flow Procedure
- SIEA collection Procedure
Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2026
- Primary completion
- Mar 31, 2030
- Completion
- Mar 31, 2030
- Last update posted
- Sep 21, 2026
2026 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07832942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2026 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07832942 live on ClinicalTrials.gov.